

## 510(k) Summary

The following 510(k) summary has been prepared pursuant to requirements specified in 21CFR§807.92(a).

### 807.92(a)(1)

#### **Submitter Information**

Carri Graham, Official Correspondent  
The Anson Group  
11460 N Meridian St., Ste 150  
Carmel, Indiana 46032  
Phone: (317) 569-9500 x103  
Facsimile: (317) 569-9520

Contact Person: Carri Graham  
Date: March 24, 2006

### 807.92(a)(2)

Trade Name: MyLab30, 50, 70, 90 Systems  
Common Name: Ultrasound Imaging System  
Classification Name(s): Ultrasonic pulse doppler imaging system 892.1550  
Ultrasonic pulsed echo imaging system 892.1560  
Classification Number: 90IYN; 90IYO

### 807.92(a)(3)

#### **Predicate Device(s)**

K040596	7300 (MyLab30)	Esaote, S.p.A.
K050326	7350 (MyLab50)	Esaote, S.p.A.
K051308	6150 (MyLab70)	Esaote, S.p.A.
K051837	6100 (MyLab90)	Esaote, S.p.A.
K043455	8000Live	Medison
K022567	Sequoia Signature II	Siemens

807.92 (a)(4)

**Device Description**

The 7300 (MyLab30), 7350 (MyLab50), 6150 (MyLab70), and 6100 (MyLab90) system designs remain the same as those previously cleared by FDA via K040596, K050326, K051308, and K051837, respectively. They are ultrasound systems used to perform diagnostic general ultrasound studies. Their primary modes of operation are: B-Mode, M-Mode, Doppler, 3D/4D and Color Flow Mapping and, on lower frequency probes, Tissue Enhancement Imaging (TEI). The systems are equipped with an optional LCD Color Display and can drive phased (PA), convex (CA) and linear array (LA) and Doppler probes.

The 30/50/70/90 systems are able to produce Real Time 2D images and 3D images (in manual mode) with all probes. The systems in combination with the BC431 or BS230 probes, offer the possibility to also produce automatic 3D and Real Time 4D images. The 7300 (MyLab30), 7350 (MyLab50), 6150 (MyLab70), and 6100 (MyLab90) models are manufactured under an ISO 9001:2000 and ISO 13485 certified quality system.

807.92(a)(5)

**Intended Use(s)**

Esaote's Model 7300 (MyLab30) is a compact ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Transesophageal, Peripheral Vascular, Neonatal Cephalic, Adult Cephalic, Small organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Transvaginal, Transrectal, Pediatric, Intraoperative: Abdominal, and Other: Urologic.

Esaote's Model 7350 (MyLab50) is a mainframe ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Transesophageal, Peripheral Vascular, Neonatal Cephalic, Adult Cephalic, Small organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Transvaginal, Transrectal, Pediatric, Intraoperative: Abdominal, and Other: Urologic.

Esaote's Model 6150 (MyLab70) is a mainframe ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Transesophageal, Peripheral Vascular, Neonatal Cephalic, Adult Cephalic, Small organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Transvaginal, Transrectal, Pediatric, Intraoperative: Abdominal, and Other: Urologic.

Esaote's Model 6100 (MyLab90) is a mainframe ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Transesophageal, Peripheral Vascular, Neonatal Cephalic, Small organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Transvaginal, Transrectal, Pediatric, Adult Cephalic, Laparoscopic, Intraoperative: Abdominal, and Other: Urologic.

807.92(a)(6)

## Technological Characteristics

Following is a comparison table indicating the additions to be made to the systems via this submission indicated by "YES", as well as previously cleared items.

To be added via this 510(k)	Siemens Sequoia Signature II K022567 (Predicate)	Medison 8000Live K043455 (Predicate)	Esaote MyLab90 (6100) K051837 (Predicate)	Esaote MyLab70 (6150) K051308 (Predicate)	Esaote MyLab30CV (7300) K040596	Esaote MyLab50 (7350) K050326
3D Mode	☑	☑	☑	☑	YES	YES
4D Mode	☑	☑	YES	YES	YES	YES
Strain Rate	☑	NO	YES	YES	YES	YES
Quantification						
Biopsy Accessories						
ABC43	NO	NO	YES	YES	YES	YES
Biopsy Kit for BS230	NO	NO	☑	☑	YES	YES
Transducers						
BC431	NO	NO	YES	YES	YES	YES
BS230	NO	NO	☑	☑	YES	YES
Indication For Use						
Urologic	NO	NO	☑	☑	YES	YES
IMT.LAB Software*	NO	NO	☑	☑	☑	☑

- ☑ Indicates that the system has been previously cleared for that item
- YES Indicates that the item is to be cleared via this submission
- NO Indicates that the item is NOT to be cleared via this submission
- \*IMT.LAB software was cleared via K043360 and runs on a stand-alone PC.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Esaote, S.p.A.  
% Ms. Carrie Graham  
Consultant  
Anson Group, LLC  
11460 N Meridian St., Ste 150  
CARMEL IN 46032

MAY 19 2006

Re: K060827

Trade Name: MyLab30, 50, 70, 90 Systems  
Regulation Number: 21 CFR 892.1550  
Regulation Name: Ultrasonic pulsed doppler imaging system  
Regulation Number: 21 CFR 892.1560  
Regulation Name: Ultrasonic pulsed echo imaging system  
Regulation Number: 21 CFR 892.1570  
Regulation Name: Diagnostic ultrasonic transducer  
Regulatory Class: II  
Product Code: IYN, IYO, and ITX  
Dated: March 24, 2006  
Received: March 27, 2006

Dear Ms. Graham:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

This determination of substantial equivalence applies to the Model 7300 (MyLab30) and 7350 (MyLab50) systems with the added BS230 and BC431 ultrasound transducers and the Model 6150 (MyLab70) and Model 6100 (MyLab90) systems with the added BC 431 ultrasound transducer.



*Protecting and Promoting Public Health*

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This determination of substantial equivalence is granted on the condition that prior to shipping the first device, you submit a postclearance special report. This report should contain complete information, including acoustic output measurements based on production line devices, requested in Appendix G, (enclosed) of the Center's September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers." If the special report is incomplete or contains unacceptable values (e.g., acoustic output greater than approved levels), then the 510(k) clearance may not apply to the production units which as a result may be considered adulterated or misbranded.

The special report should reference the manufacturer's 510(k) number. It should be clearly and prominently marked "ADD-TO-FILE" and should be submitted in duplicate to:

Food and Drug Administration  
Center for Devices and Radiological Health  
Document Mail Center (HFZ-401)  
9200 Corporate Boulevard  
Rockville, Maryland 20850

This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>

Page 3 – Ms. Graham

If you have any questions regarding the content of this letter, please contact Andrew Kang, M.D.  
at (301) 594-1212.

Sincerely yours,

A handwritten signature in cursive script that reads "Nancy C. Brogdon".

Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure(s)

## Indications for Use

510(k) Number (if known): K 060827

Device Name: MyLab30, 50, 70, 90 Systems addition of 3D/4D

### Indications For Use:

Esaote's Model 7300 (MyLab30) is a compact ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Transesophageal, Peripheral Vascular, Neonatal Cephalic, Adult Cephalic, Small organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Transvaginal, Transrectal, Pediatric, Intraoperative: Abdominal, and Other: Urologic.

Esaote's Model 7350 (MyLab50) is a mainframe ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Transesophageal, Peripheral Vascular, Neonatal Cephalic, Adult Cephalic, Small organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Transvaginal, Transrectal, Pediatric, Intraoperative: Abdominal, and Other: Urologic.

Esaote's Model 6150 (MyLab70) is a mainframe ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Transesophageal, Peripheral Vascular, Neonatal Cephalic, Adult Cephalic, Small organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Transvaginal, Transrectal, Pediatric, Intraoperative: Abdominal, and Other: Urologic.

Esaote's Model 6100 (MyLab90) is a mainframe ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Transesophageal, Peripheral Vascular, Neonatal Cephalic, Small organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Transvaginal, Transrectal, Pediatric, Adult Cephalic, Laparoscopic, Intraoperative: Abdominal, and Other: Urologic.

Prescription Use X  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Nancy C. Broglon  
(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number K060827

Page 1 of 1

# Diagnostic Ultrasound Indications for Use Form

## Model 7300 (MyLab30)

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal		P	P	P		P	P		P [2]	P [3], N[4]
Abdominal		P	P	P		P	P		P [2]	P [3], N[4]
Intraoperative (Abdominal)		P	P	P		P	P		P [2]	P [3]
Intraoperative Neurological										
Pediatric		P	P	P	P	P	P		P [2]	P [3], N[4]
Small Organ (specify) [1]		P	P	P	P	P	P		P [2]	P [3]
Neonatal Cephalic		P	P	P	P	P	P		P [2]	
Adult Cephalic		P	P	P	P	P	P		P [2]	
Cardiac		P	P	P	P	P			P [2]	P [3], N[4]
Transesophageal		P	P	P	P	P	P		P [2]	
Transrectal		P	P	P		P	P		P [2]	
Transvaginal		P	P	P		P	P		P [2]	
Transurethral										
Intravascular										
Peripheral Vascular		P	P	P	P	P	P		P [2]	
Laparoscopic										
Musculo-skeletal Conventional		P	P	P	P	P	P		P [2]	
Musculo-skeletal Superficial		P	P	P	P	P	P		P [2]	
Other (Urological)		N	N	N	N	N	N		N [2]	

N=new indication; P=previously cleared by FDA; E= added under Appendix E


### Additional Comments:

- [1] Small organs include Thyroid, Breast and Testicles.
- [2] Applicable combined modes: B+M+PW+CW+CFM+PD
- [3] Tissue Enhancement Imaging (TEI)  
Compound Imaging  
VPAN  
Tissue Velocity Mapping (TVM)  
CMM  
CnTI
- [4] 3D/4D Imaging

(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED)

concurrency of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal,  
 and Radiological Devices  
 510(k) Number 4060827



# Diagnostic Ultrasound Indications for Use Form

## Model 7350 (MyLab50)

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal		P	P	P		P	P		P [2]	P [3], N[4]
Abdominal		P	P	P		P	P		P [2]	P [3], N[4]
Intraoperative (Abdominal)		P	P	P		P	P		P [2]	P [3]
Intraoperative Neurological										
Pediatric		P	P	P	P	P	P		P [2]	P [3], N[4]
Small Organ (specify) [1]		P	P	P	P	P	P		P [2]	P [3]
Neonatal Cephalic		P	P	P	P	P	P		P [2]	
Adult Cephalic		P	P	P	P	P	P		P [2]	P [3]
Cardiac		P	P	P	P	P			P [2]	P [3], N[4]
Transesophageal		P	P	P	P	P			P [2]	
Transrectal		P	P	P		P	P		P [2]	
Transvaginal		P	P	P		P	P		P [2]	
Transurethral										
Intravascular										
Peripheral Vascular		P	P	P	P	P	P		P [2]	
Laparoscopic										
Musculo-skeletal Conventional		P	P	P	P	P	P		P [2]	
Musculo-skeletal Superficial		P	P	P	P	P	P		P [2]	
Other (Urological)		N	N	N	N	N	N		N [2]	

N=new indication; P=previously cleared by FDA; E= added under Appendix E

### Additional Comments:

- [1] Small organs include Thyroid, Breast and Testicles.
- [2] Applicable combined modes: B+M+PW+CW+CFM+PD
- [3] Tissue Harmonic Imaging (TEI)  
CMM  
Tissue Velocity Mapping (TVM)  
VPAN  
Compound Imaging  
CnTI
- [4] 3D/4D Imaging

(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED)

concurrency of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

(Division Sign-Off)

Division of Reproductive, Abdominal,  
and Radiological Devices

510(k) Number

*Nancy C. Proff*  
*K060827*

# Diagnostic Ultrasound Indications for Use Form

## Model 6150 (MyLab70)

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal		P	P	P	P	P	P		P [2]	P [3], N[4]
Abdominal		P	P	P	P	P	P		P [2]	P [3], N[4]
Intraoperative (Abdominal)		P	P	P	P	P	P		P [2]	P [3]
Intraoperative Neurological										
Pediatric		P	P	P	P	P	P		P [2]	P [3], N[4]
Small Organ (specify) [1]		P	P	P	P	P	P		P [2]	P [3]
Neonatal Cephalic		P	P	P	P	P	P		P [2]	P [3]
Adult Cephalic		P	P	P	P	P	P		P [2]	P [3]
Cardiac		P	P	P	P	P	P		P [2]	P [3], N[4]
Transesophageal		P	P	P	P	P	P		P [2]	P [3]
Transrectal		P	P	P		P	P		P [2]	P [3]
Transvaginal		P	P	P		P	P		P [2]	P [3]
Transurethral										
Intravascular										
Peripheral Vascular		P	P	P	P	P	P		P [2]	P [3]
Laparoscopic										
Musculo-skeletal Conventional		P	P	P	P	P	P		P [2]	P [3]
Musculo-skeletal Superficial		P	P	P	P	P	P		P [2]	P [3]
Other (Urological)		P	P	P	P	P	P		P [2]	P [3]


N=new indication; P=previously cleared by FDA; E= added under Appendix E

### Additional Comments:

- [1] Small organs include Thyroid, Breast and Testicles.
- [2] Applicable combined modes: B+M+PW+CW+CFM+PD
- [3] Tissue Harmonic Imaging (TEI)
  - CMM
  - VPAN
  - Compound Imaging
  - CnTI
  - Tissue Velocity Mapping (TVM)
  - 3D Imaging
- [4] 4D Imaging

(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED)

concurrency of CDRH, Office of Device Evaluation (ODE)  
Prescription Use (Per 21 CFR 801.109)

  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal,  
 and Radiological Devices  
 510(k) Number K060827

# Diagnostic Ultrasound Indications for Use Form

## Model 6100 (MyLab90)

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

Clinical Application	Mode of Operation									
	A	B	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal		P	P	P	P	P	P		P [2]	P [3], N[4]
Abdominal		P	P	P	P	P	P		P [2]	P [3], N[4]
Intraoperative (Abdominal)		P	P	P	P	P	P		P [2]	P [3]
Intraoperative Neurological										
Pediatric		P	P	P	P	P	P		P [2]	P [3], N[4]
Small Organ (specify) [1]		P	P	P	P	P	P		P [2]	P [3]
Neonatal Cephalic		P	P	P	P	P	P		P [2]	P [3]
Adult Cephalic		P	P	P	P	P	P		P [2]	P [3]
Cardiac		P	P	P	P	P	P		P [2]	P [3], N[4]
Transesophageal		P	P	P	P	P	P		P [2]	P [3]
Transrectal		P	P	P	P	P	P		P [2]	P [3]
Transvaginal		P	P	P	P	P	P		P [2]	P [3]
Transurethral										
Intravascular										
Peripheral Vascular		P	P	P	P	P	P		P [2]	P [3]
Laparoscopic		P	P	P	P	P	P		P [2]	P [3]
Musculo-skeletal Conventional		P	P	P	P	P	P		P [2]	P [3]
Musculo-skeletal Superficial		P	P	P	P	P	P		P [2]	P [3]
Other (Urological)		P	P	P	P	P	P		P [2]	P [3]

N=new indication; P=previously cleared by FDA; E= added under Appendix E

### Additional Comments:

- [1] Small organs include Thyroid, Breast and Testicles.
- [2] Applicable combined modes: B+M+PW+CW+CFM+PD
- [3] Tissue Harmonic Imaging (TEI)
  - CMM
  - VPAN
  - Compound Imaging
  - CnTI
  - Tissue Velocity Mapping (TVM)
  - 3D Imaging
- [4] 4D Imaging

Peripheral Vascular to include Vein Mapping & Sclerotherapy

(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED  
concurrence of CDRH, Office of Device Evaluation (ODE)  
Prescription Use (Per 21 CFR 801.109)

*Nancy C. Brogdon*  
\_\_\_\_\_  
(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number 2060827

# 7300, 7350, 6150 and 6100 Systems

BC431

Clinical Application	Mode of Operation									
	A	B	M	PWD (PW)	CWD (CW)	Color Doppler (CFM)	Amplitude Doppler (PD)	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal		N	N	N		N	N		N (1)	N (2), N[3]
Abdominal		N	N	N		N	N		N (1)	N (2), N[3]
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric		N	N	N		N	N		N (1)	N (2), N[3]
Small Organ (specify)										
Neonatal Cephalic										
Adult Cephalic										
Cardiac										
Transesophageal										
Transrectal										
Transvaginal										
Transurethral										
Intravascular										
Peripheral Vascular		N	N	N		N	N		N (1)	N (2)
Laparoscopic										
Musculo-skeletal Conventional										
Musculo-skeletal Superficial										
Other (Urological)		N	N	N		N	N		N (1)	N (2)

N= new indication; P= previously cleared by FDA; E= added under Appendix E

[1] Applicable combined modes: B+M+PW+CFM+PD

[2] Tissue Harmonic Imaging (TEI)

CMM

VPAN

Compound Imaging

CnTI

Tissue Velocity Mapping (TVM)

[3] 3D/4D Imaging

(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED)

concurrency of CDRH, Office of Device Evaluation (ODE)  
Prescription Use (Per 21 CFR 801.109)

*Nancy C. Brogdon*  
(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number 4060827

# 7300 and 7350 Systems

BS230

Clinical Application	Mode of Operation									
	A	B	M	PWD (PW)	CWD (CW)	Color Doppler (CFM)	Amplitude Doppler (PD)	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal										
Abdominal		N	N	N	N	N	N		N (1)	N (2), N[3]
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric										
Small Organ (specify)										
Neonatal Cephalic										
Adult Cephalic		N	N	N	N	N	N		N (1)	N (2), N[3]
Cardiac		N	N	N	N	N	N		N (1)	N (2), N[3]
Transesophageal										
Transrectal										
Transvaginal										
Transurethral										
Intravascular										
Peripheral Vascular										
Laparoscopic										
Musculo-skeletal Conventional										
Musculo-skeletal Superficial										
Other (Urological)										

N= new indication; P= previously cleared by FDA; E= added under Appendix E

[1] Applicable combined modes: B+M+PW+CW+CFM+PD

[2] Tissue Harmonic Imaging (TEI)

Compound Imaging

CnTI

[3] 3D/4D Imaging

(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED)

concurrency of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

(Division Sign-Off)

Division of Reproductive, Abdominal,  
and Radiological Devices

510(k) Number

*Nancy C. Brodson*

*4060827*

# 6150 and 6100 Systems

BS230

Clinical Application	Mode of Operation									
	A	B	M	PWD (PW)	CWD (CW)	Color Doppler (CFM)	Amplitude Doppler (PD)	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic										
Fetal										
Abdominal		P	P	P	P	P	P		P (1)	P (2), N[3]
Intraoperative (specify)										
Intraoperative Neurological										
Pediatric										
Small Organ (specify)										
Neonatal Cephalic										
Adult Cephalic		P	P	P	P	P	P		P (1)	P (2), N[3]
Cardiac		P	P	P	P	P	P		P (1)	P (2), N[3]
Transesophageal										
Transrectal										
Transvaginal										
Transurethral										
Intravascular										
Peripheral Vascular										
Laparoscopic										
Musculo-skeletal Conventional										
Musculo-skeletal Superficial										
Other (Urological)										

N= new indication; P= previously cleared by FDA; E= added under Appendix E

[1] Applicable combined modes: B+M+PW+CW+CFM+PD

[2] Tissue Harmonic Imaging (TEI)

Compound Imaging

CnTI

3D Imaging

[3] 4D Imaging

(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED)

concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

*Nancy C Brogdon*  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal,  
 and Radiological Devices  
 510(k) Number K060827